Combo Tx Improves BMD at Spine, Hip

Major Findings: Treatment with teriparatide plus zoledronic acid increased spinal bone mineral density more than either drug alone.

Source of Data: One-year study of 412 postmenopausal women with previously untreated osteoporosis.

Disclosures: The study was sponsored by Novartis, which makes Zometa. Dr. Cosman reported that she has received consulting fees from Novartis and other pharmaceutical companies.